Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces

Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the last private round can understate value by 10-20X, how Canaan builds management teams around a key individual who sets the tone and why biotech needs scientific heroes as AI captures most venture dollars.

View full story: https://www.biocentury.com/article/660963

#VentureCapital #Biotech #WomensHealth #DrugDevelopment #BiotechMA

0:00 Introduction
1:19 Canaan's Strategy
11:34 Team Building
21:57 White Space
28:00 New Biotech Buyers
34:15 Biotech Founders